Alaunos Therapeutics, Inc. (TCRT)

Every figure this model derived for TCRT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 98,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 124,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 666,000 AssetsCurrent 2026-06-30
current liabilities 864,000 LiabilitiesCurrent 2026-06-30
equity 652,000 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2025-12-31
ocf -2,727,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 931,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TCRT on one particular measure came for.

RatioValue
current ratio0.77
current ratio reported0.77
deferred revenue growth674.97
dilution pct21.69
growth cv2.87
revenue growth-50.0
revenue growth per share-58.91
roic-607.16
rpo growth0.0
rule of 40-135316.67

What to be careful about

What this model itself distrusts about TCRT's figures. Written by the derivation as it ran, not added afterwards.